PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Triamcinolone acetonide - Allergic rhinitis

PAD Profile : Triamcinolone acetonide - Allergic rhinitis

Keywords :
Hay fever, hayfever, allergy, seasonal allergic rhinitis, pollen allergy, corticosteroids, corticosteroid injections
Brand Names Include :
Kenalog, Nasacort

Traffic Light Status

Status 1 of 2.

Status :
Non Formulary
Formulations :
  • Injection
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Green (see narrative)
Important
Formulations :
  • Nasal spray
Important Information :
Beclometasone (200 dose container) is the preferred intranasal steroid for allergic rhinitis. Triamcinolone is considered to be a 3rd / 4th line agent.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Guidelines (Local)
01 January 2024

Committee Recommendations

Date
Committee Name
Narrative
05 April 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Depot steroids should not be prescribed for hay fever. Evidence of safety is lacking, and there is a significant risk of prolonged side-effects (e.g. osteoporosis) which cannot be mitigated by withdrawal of the drug

05 April 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Triamcinolone nasal spray is considered to be a 3rd / 4th line agent for nasal allergic rhinitis - see local guidelines below. 

Associated BNF Codes

06. Endocrine System
06.03.02. Glucocorticoid therapy
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More